Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach

Cancer ◽  
2021 ◽  
Author(s):  
Hagop M. Kantarjian ◽  
Tapan M. Kadia ◽  
Courtney D. DiNardo ◽  
Mary Alma Welch ◽  
Farhad Ravandi
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Leukemia Treatment ◽  
Md Anderson ◽  
Acute Myeloid

Gelatin-coated Gold Nanoparticles as Carriers of FLT3 Inhibitors for Acute Myeloid Leukemia Treatment

2016 ◽  
Vol 87 (6) ◽  
pp. 927-935 ◽  
Author(s):  
Sorina Suarasan ◽  
Timea Simon ◽  
Sanda Boca ◽  
Ciprian Tomuleasa ◽  
Simion Astilean
Keyword(s):  
Gold Nanoparticles ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Flt3 Inhibitors ◽  
Leukemia Treatment ◽  
Acute Myeloid

scholarly journals Is Need Chemotherapy Titration During Acute Myeloid Leukemia Treatment?

2021 ◽  
pp. 1-5
Author(s):  
Ali Amanati ◽  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Minimal Residual Disease ◽  
Myeloid Leukemia ◽  
Poor Prognosis ◽  
Residual Disease ◽  
Rare Complication ◽  
Intensive Chemotherapy ◽  
Leukemia Treatment ◽  
Minimal Residual ◽  
Acute Myeloid

Persistent marrow aplasia is a rare complication with poor prognosis after intensive chemotherapy for acute myeloid leukemia. We present a 14-year-old boy with acute myeloid leukemia (AML), was complicated by chemotherapy induced persistent aplasia and he was expired because of prolonged neutropenia and pulmonary Aspergilosis. In this review we explain causes of persistent post chemotherapy persistent aplasia and prevention of this phenomenon during treatment with consideration of minimal residual disease (MRD) and response to question about chemotherapy titration dose.

scholarly journals Outcomes of pediatric acute myeloid leukemia treatment in Western Kenya

2021 ◽  
Author(s):  
Romy E. Weelderen ◽  
Festus Njuguna ◽  
Kim Klein ◽  
Saskia Mostert ◽  
Sandra Langat ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Western Kenya ◽  
Pediatric Acute Myeloid Leukemia ◽  
Leukemia Treatment ◽  
Acute Myeloid

Evaluation of Poly(ADP-ribose) Polymerase Inhibitor, Pamiparib (BGB-290) in Treating Acute Myeloid Leukemia and the Characterization of Its Nanocarrier

2021 ◽  
Vol 17 (11) ◽  
pp. 2165-2175
Author(s):  
Xi Xu ◽  
Jian Wang ◽  
Tong Tong ◽  
Shao-Fen Lin ◽  
Congmin Liu ◽  
...  
Keyword(s):  
Dna Damage ◽  
Acute Myeloid Leukemia ◽  
Cell Lines ◽  
Myeloid Leukemia ◽  
Parp Inhibitor ◽  
Chemotherapy Resistance ◽  
Disease Free Survival ◽  
Plga Nanoparticles ◽  
Leukemia Treatment ◽  
Acute Myeloid

Despite the continuous improvement of leukemia treatment in the clinic, the overall 5-year disease-free survival of acute myeloid leukemia (AML) is only approximately 30%–60% due to relapse and the refractoriness of AML after traditional chemotherapy. Inhibition of poly(ADP-ribose) polymerase (PARP), a member of the DNA damage repair complex, has a strong antitumor effect in solid tumors. However, the role of PARP in AML remains unclear. We found that high levels of PARP1 and PARP2 were positively related to chemotherapy resistance and poor prognosis in patients with AML. Doxorubicin (DOX)-resistant AML cells highly expressed PAPR1 and PARP2. Knockdown of PARP1 and PARP2, or pharmaceutical inhibition of PARP by the PARP inhibitor (PARPi) BGB-290, significantly enhanced the cytotoxicity of DOX in AML cells due to increased DNA damage. PLGA-loading BGB-290 was properly self-assembled into stable BGB-290@PLGA nanoparticles (NPs), which is uniform particle size and good stability. BGB-290@PLGA is easily uptake by AML cell lines and stays for a long time. Combined with DOX, BGB-290@PLGA can significantly improve the chemosensitivity of AML cell lines. Furthermore, BGB-290 and DOX combination treatment dramatically repressed the onset of leukemia and prolonged the survival of THP-1 xenografted mice. Overall, this study demonstrated that PARPi with traditional chemotherapy could be an efficient therapeutic strategy for AML.

Side effects from acute myeloid leukemia treatment: results from a national survey

2019 ◽  
Vol 35 (11) ◽  
pp. 1965-1970 ◽  
Author(s):  
Norah L. Crossnohere ◽  
Daniel R. Richardson ◽  
Crystal Reinhart ◽  
Bernadette O’Donoghue ◽  
Susan M. Love ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Side Effects ◽  
National Survey ◽  
Myeloid Leukemia ◽  
Treatment Results ◽  
Leukemia Treatment ◽  
Acute Myeloid

scholarly journals Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment

2020 ◽  
Vol 21 (16) ◽  
pp. 5626
Author(s):  
Laurène Fenwarth ◽  
Elise Fournier ◽  
Meyling Cheok ◽  
Thomas Boyer ◽  
Fanny Gonzales ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Residual Disease ◽  
Response Prediction ◽  
Gemtuzumab Ozogamicin ◽  
Nucleotide Polymorphisms ◽  
Molecular Alterations ◽  
Leukemia Treatment ◽  
Set Up ◽  
Acute Myeloid

Gemtuzumab ozogamicin (GO, Mylotarg®) consists of a humanized CD33-targeted antibody-drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute myeloid leukemia (AML), demonstrated by improved outcomes in CD33-positive AML patients across phase I to III clinical trials, led to the Food and Drug Administration (FDA) approval on 1 September 2017 in CD33-positive AML patients aged 2 years and older. Discrepancies in GO recipients outcome have raised significant efforts to characterize biomarkers predictive of GO response and have refined the subset of patients that may strongly benefit from GO. Among them, CD33 expression levels, favorable cytogenetics (t(8;21), inv(16)/t(16;16), t(15;17)) and molecular alterations, such as NPM1, FLT3-internal tandem duplications and other signaling mutations, represent well-known candidates. Additionally, in depth analyses including minimal residual disease monitoring, stemness expression (LSC17 score), mutations or single nucleotide polymorphisms in GO pathway genes (CD33, ABCB1) and molecular-derived scores, such as the recently set up CD33_PGx6_Score, represent promising markers to enhance GO response prediction and improve patient management.

Sign in / Sign up

Export Citation Format

Share Document